Telik Inc. Message Board
-
Hi Guys ..
Intelgenx launched their first drug Forfivo in October this will drive Intelgenx into Profitability this Year because of its very low burn-rate of around $1.2 Mil a year !
IGXT Submits NDA for Anti-Migraine Versafilm to FDA in March another 1x NDA filing for Erectile Dysfunction Versafilm and 2x ANDA filings expected in 1H 2013. Two Partnerships for Anti-Migraine and Erectile Dysfunction products is expected in 1H 2013 too which means more Cash for Intelgenx .Intelgenx has 9x Drugs in late stage which will be all on the Market within next 2-3 years .
IGXT has NO DEBT and Cash untill 2016 means enough to drive this Company into Profitability which is expected for this Year . Current Market Cap of just $31 M is really Brutally Underpriced .
IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $31 M
Cash: $3.5 M
Burn-Rate : $1.2 M a year
Price : $0.63
Shares Out : 50 M ( 20 M shares are held by Insiders & Institutions)
March 27, 2013 IntelGenx Corp. a Canadian drug delivery company focusing on oral drug delivery, today announced that, together with its co-development partner RedHill Biopharma ("RedHill"), it has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for the Company's anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilm(TM) technology containing Rizatriptan, the active drug in Merck's Maxalt-MLT(R) orally disintegrating tablets.
"We are very excited that our first FDA-approved product, Forfivo XL(TM), has been launched in the USA in early October by our partner Edgemont Pharmaceuticals. We believe that ForFivo XL(TM), as the only single tablet 450mg bupropion HCl available in the U.S., will be a valuable tool for physicians in their management of patients with major depressive disorders," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx.
-,-,. -
..telik negative past don't give you the right to post false informations...
-
it's easy...like 123...
"...Orphan Designation: Treatment of myelodysplastic syndrome
Orphan Designation Status: Designated.." -
Your snap, one sentence, pure unsupported opinions are great.
Now try googling every line of the original message and see about "Telik ethics" and Icahn worst and the people who were laid off etc. Be careful whom you call a liar, Bucko! -
TELK has been showing support around 1.17 and resistance in the 1.57 price range. 78% chance up at foxchart website.
-
..off topic.. .. "reality check" is in reality a big stupid lie...
-
That opinion does not take into account of WHO was laid off. Case in point, the "Product Development" guy, Steuer. Guess no product is on the cusp of being developed. Virtually all of the TRAP librarians and quality scientists are gone. Only people left are legal and pencil pushers.
-
..there was a third possibility...you are very ignorant and liar...now you know the difference between designation and approval...for sure it will works out for you...
-
Sounds like a great opportunity.
I would be pleased to see you put all your family savings in Telik stock. I hope it works out for you. -
..2 possibilities...you are very ignorant or very liar...one thing is designation another is approval...the compound is clearly not approved to be sold....it will be necessary a phase III...but it's fda designated orphan drug.....
Palo Alto, CA – January 11, 2013 – Telik, Inc. (Nasdaq: TELK) was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS). Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval. Additional potential benefits of orphan designation include development grants, tax credits related to clinical trial expenses, protocol development assistance and exemption from FDA user fees. The US Orphan Drug Act aims to encourage the development of drugs for the diagnosis, prevention and treatment of medical conditions affecting fewer than 200,000 people in the US. -
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
-
...Orphan Designation: Treatment of myelodysplastic syndrome
Orphan Designation Status: Designated.. -
The village idiots have taken refuge in the BOD - this is a loser company with loser people running it.
They bank on announcements and SA articles to over hype it so they can issue more shares.
This is a no brainer...and i refer to the CEO whem I say this. -
they are going to dillute the shares sell it while you still have a chance. I see 70. cents coming, Buy ONCY a way better company with a number of phase 3 in trials.
-
How many stockholders out there think $514k/year plus bonus' is perfectly fair compensation for the CEO of a 17 employee company with no products ever produced? Show by Thumbs up (fair) or thumbs down for (unfair)
-
telk should outsource the reverse split scam to Warrel and loretta of Genta they know how to work the system and get away with fraud.
-
What can be learnt from Genta is that a husband and wife team is a huge scam, Vow, history does repeat itself. may be
http://www.thestreet.com/story/11747573/1/genta-1998-2012.html?puc=yahoo&cm_ven=YAHOO -
Watch RCON on Thursday make back losses from TELK
-
Disclosed number of employees went from 22 to N/A and now to 17. Getting close to the end of this drama.
-
yeah they are about to run ...out of money....see you a the next chapter of their book.....11
One Year After IPO, Facebook's Biggest Bets Could Take a Long Time to Pay Off
Wochit - 14 hours agoGoogle's Wearable Glass Gadget: Cool or Creepy?
Wochit - 17 hours agoEU Official Cites Chinese Telecoms Huawei and ZTE for Trade Violations
Wochit - 21 hours ago